Washington, D.C. 20549






Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

For the month of August, 2022

Commission File Number 001-39670




(Translation of registrant’s name into English)



6 Tide Street, Suite 400

Boston, Massachusetts 02210

(Address of principal executive office)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐





On May 9, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) announced the commencement of a $50 million share repurchase program (the “Program”) of its ordinary shares of one pence each (“Ordinary Shares”). The Company plans to execute the Program in two equal tranches. In respect of the first tranche, PureTech entered into an irrevocable non-discretionary instruction with Jefferies International Limited (“Jefferies”) in relation to the purchase by Jefferies of Ordinary Shares for an aggregate consideration (excluding expenses) of no greater than $25 million and the simultaneous on-sale of such Ordinary Shares by Jefferies to PureTech. Jefferies makes its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Company. Purchases may continue during any close period to which the Company is subject. Any purchase of Ordinary Shares under the first tranche of the Program are carried out on the London Stock Exchange and any other UK recognized investment exchange which may be agreed, in accordance with pre-set parameters and in accordance with, and subject to limits, including those limits related to daily volume and price, prescribed by the Company’s general authority to repurchase Ordinary Shares granted by its shareholders at its most recent annual general meeting on May 27, 2021, Chapter 12 of the Financial Conduct Authority’s UK Listing Rules, Article 5(1) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018). All Ordinary Shares repurchased under the Program will be held in treasury.

During the month ended August 31, 2022, the Company had the following daily purchases of its own Ordinary Shares under the Program through Jefferies:



   Ordinary Shares
     Volume Weighted
Average Price Paid
per Ordinary Share
     Highest Price Paid      Lowest Price Paid  

August 1, 2022

     60,600        197.90p        199.40p        195.00p  

August 2, 2022

     61,631        199.64p        205.00p        195.00p  

August 3, 2022

     59,358        199.84p        201.00p        198.60p  

August 4, 2022

     59,666        199.10p        201.50p        195.00p  

August 5, 2022

     57,709        197.72p        200.50p        195.00p  

August 8, 2022

     17,329        202.02p        205.50p        198.00p  

August 12, 2022

     23,039        226.43p        231.00p        224.00p  

August 16, 2022

     12,947        242.34p        242.50p        241.00p  

August 17, 2022

     33        244.50p        244.50p        244.50p  

August 18, 2022

     60,974        252.23p        253.00p        250.00p  

August 19, 2022

     51,958        257.87p        258.50p        255.00p  

August 22, 2022

     62,945        253.80p        261.00p        250.00p  

August 23, 2022

     65,853        256.47p        262.50p        248.00p  

August 24, 2022

     67,196        249.68p        252.00p        247.00p  

August 25, 2022

     69,733        249.86p        258.00p        245.50p  

August 26, 2022

     73,629        250.00p        255.00p        244.00p  

August 30, 2022

     75,713        239.08p        243.00p        233.50p  

August 31, 2022

     75,669        250.71p        255.50p        240.50p  

During the month ended August 31, 2022, the Company repurchased an aggregate of 955,982 Ordinary Shares. As of August 31, 2022, the Company’s issued share capital was 289,012,903 shares, 4,972,839 of which were held in treasury, resulting in total voting rights in the Company of 284,040,064 shares. To view the details of the individual transactions, please paste the following URL(s) into the address bar of your browser with respect to each individual date of repurchase under the Program:

August 1, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4460460.html

August 2, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4462200.html

August 3, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4463824.html

August 4, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4465348.html

August 5, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4466958.html

August 8, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4468523.html

August 12, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4474657.html

August 16, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4477729.html

August 17, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4479142.html

August 18, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4480685.html

August 19, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4482160.html

August 22, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4483582.html

August 23, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4485224.html

August 24, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4486777.html

August 25, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4488180.html

August 26, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4490035.html

August 30, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4492013.html

August 31, 2022: https://data.fca.org.uk/artefacts/NSM/RNS/4493810.html


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.




Date: September 2, 2022




/s/ Daphne Zohar




Daphne Zohar




Chief Executive Officer